Refractory infantile spasms associated with mosaic variegated aneuploidy syndrome

Noriyuki Akasaka1, Jun Tohyama, Atsushi Ogawa

  • 1Department of Child Neurology, Nishi-Niigata Chuo National Hospital, Niigata, Japan.

Pediatric Neurology
|August 7, 2013
PubMed
Abstract

Insights

Mosaic variegated aneuploidy syndrome, a rare cancer-prone disorder, can present with severe developmental brain anomalies leading to early-onset epileptic encephalopathy. Early diagnosis and genetic counseling are crucial for affected families.

Area of Science:

  • Genetics
  • Oncology
  • Neurology

Background:

  • Mosaic variegated aneuploidy syndrome (MVAS), also known as premature chromatid separation syndrome, is a rare autosomal recessive disorder linked to BUB1B gene mutations.
  • It is characterized by a high risk of malignancy, including rhabdomyosarcoma, Wilms tumor, and leukemia.
  • Clinical manifestations include prenatal growth retardation, microcephaly, dysmorphism, feeding difficulties, hypotonia, seizures, and developmental delay.

Purpose of the Study:

  • To report a case of MVAS with significant developmental brain anomalies and early-onset epileptic encephalopathy.
  • To highlight the association between MVAS and neurological complications.
  • To emphasize the importance of recognizing MVAS for diagnosis and genetic counseling.

Main Methods:

  • A case study of a male infant with severe developmental delay, microcephaly, hypotonia, and intractable seizures.
  • Magnetic resonance imaging revealed Dandy-Walker malformation.
  • Chromosomal analysis confirmed mosaic variegated aneuploidy with premature chromatid separation.

Main Results:

  • The patient presented with refractory infantile spasms and hypsarrhythmia.
  • Wilms tumor and an intraorbital tumor were diagnosed at 22 months.
  • Chromosomal analysis revealed mosaic variegated aneuploidy in 59.5% of cells, with premature chromatid separation observed across all chromosomes.

Conclusions:

  • Mosaic variegated aneuploidy syndrome can be associated with developmental brain anomalies causing early-onset epileptic encephalopathy.
  • Increased awareness of MVAS is vital for accurate diagnosis and appropriate genetic counseling.
  • This case underscores the complex clinical spectrum of MVAS, extending to severe neurological impairments.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...